Compare CRESY & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRESY | DBVT |
|---|---|---|
| Founded | 1936 | 2002 |
| Country | Argentina | France |
| Employees | N/A | 90 |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 804.3M | 850.9M |
| IPO Year | 1997 | 2014 |
| Metric | CRESY | DBVT |
|---|---|---|
| Price | $12.05 | $10.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $15.86 | ★ $38.77 |
| AVG Volume (30 Days) | 299.5K | ★ 377.5K |
| Earning Date | 11-09-2026 | 10-28-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,636,000.00 |
| Revenue This Year | $14.96 | N/A |
| Revenue Next Year | $19.02 | $2,182.76 |
| P/E Ratio | $6.92 | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $8.91 | $10.23 |
| 52 Week High | $14.21 | $26.19 |
| Indicator | CRESY | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 52.57 | 28.31 |
| Support Level | $12.06 | N/A |
| Resistance Level | $12.70 | $14.90 |
| Average True Range (ATR) | 0.46 | 0.51 |
| MACD | -0.11 | -0.12 |
| Stochastic Oscillator | 56.25 | 2.33 |
Cresud SACIF y A is a Latin American agricultural firm producing basic commodities with a growing presence in Argentina, Brazil, and other countries through its investment in Brasilagro. It focuses on grains, sugarcane, and cattle farming, acquiring and developing agricultural properties for production or value appreciation, and occasionally selling appreciated land. It also leases land and offers agency and agro-industrial services. Operations are divided into two segments: agricultural business (production, land transformation and sales, corporate services) and urban properties and investments (shopping malls, offices, sales, developments, hotels, and related activities).
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.